Inactivity of Peptidase ClpP Causes Primary Accumulation of Mitochondrial Disaggregase ClpX with Its Interacting Nucleoid Proteins, and of mtDNA by Key, Jana et al.
cells
Article
Inactivity of Peptidase ClpP Causes Primary Accumulation of
Mitochondrial Disaggregase ClpX with Its Interacting Nucleoid
Proteins, and of mtDNA
Jana Key 1, Sylvia Torres-Odio 1,2, Nina C. Bach 3, Suzana Gispert 1, Gabriele Koepf 1, Marina Reichlmeir 1,4 ,
A. Phillip West 2 , Holger Prokisch 5 , Peter Freisinger 6 , William G. Newman 7,8, Stavit Shalev 9,
Stephan A. Sieber 3, Ilka Wittig 10,11 and Georg Auburger 1,*


Citation: Key, J.; Torres-Odio, S.;
Bach, N.C.; Gispert, S.; Koepf, G.;
Reichlmeir, M.; West, A.P.; Prokisch,
H.; Freisinger, P.; Newman, W.G.;
et al. Inactivity of Peptidase ClpP
Causes Primary Accumulation of
Mitochondrial Disaggregase ClpX
with Its Interacting Nucleoid Proteins,
and of mtDNA. Cells 2021, 10, 3354.
https://doi.org/10.3390/
cells10123354
Academic Editor: Plamena R.
Angelova
Received: 2 November 2021
Accepted: 25 November 2021
Published: 29 November 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Experimental Neurology, Faculty of Medicine, Goethe University, 60590 Frankfurt, Germany;
jana.key88@gmail.com (J.K.); torres.odio@exchange.tamu.edu (S.T.-O.);
Gispert-Sanchez@em.uni-frankfurt.de (S.G.); Gabriele.Koepf@kgu.de (G.K.);
Marina.Reichlmeir@gmail.com (M.R.)
2 Department of Microbial Pathogenesis and Immunology, College of Medicine, Health Science Center,
Texas A&M University, Bryan, TX 77807, USA; awest@tamu.edu
3 Center for Protein Assemblies, Chair of Organic Chemistry II, Technical University of Munich,
Ernst-Otto-Fischer-Strasse 8, 85748 Garching, Germany; nina.bach@tum.de (N.C.B.);
stephan.sieber@tum.de (S.A.S.)
4 Faculty of Biosciences, Geothe University, Altenhöferallee 1, 60438 Frankfurt am Main, Germany
5 Institute of Neurogenomics, Helmholtz Zentrum München, 85764 Neuherberg, Germany;
prokisch@helmholtz-muenchen.de
6 Department of Paediatrics, Kreisklinikum Reutlingen, 72764 Reutlingen, Germany; Freisinger_P@klin-rt.de
7 Division of Evolution Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and
Health, University of Manchester, Manchester M13 9PL, UK; William.newman@manchester.ac.uk
8 Manchester Centre for Genomic Medicine, St Mary’s Hospital, Manchester University NHS Foundation Trust,
Manchester M13 9PL, UK
9 Genetic Institute, Emek Medical Center, Afula, Rappaport Faculty of Medicine, Technion—Israel Institute of
Technology, Haifa 3200003, Israel; stavit_sh@clalit.org.il
10 Functional Proteomics, Institute for Cardiovascular Physiology, Medical Faculty, Goethe University,
60596 Frankfurt am Main, Germany; wittig@med.uni-frankfurt.de
11 German Center for Cardiovascular Research (DZHK), Partner Site RheinMain,
60596 Frankfurt am Main, Germany
* Correspondence: auburger@em.uni-frankfurt.de; Tel.: +49-(0)-69-6301-7428
Abstract: Biallelic pathogenic variants in CLPP, encoding mitochondrial matrix peptidase ClpP, cause
a rare autosomal recessive condition, Perrault syndrome type 3 (PRLTS3). It is characterized by
primary ovarian insufficiency and early sensorineural hearing loss, often associated with progressive
neurological deficits. Mouse models showed that accumulations of (i) its main protein interactor, the
substrate-selecting AAA+ ATPase ClpX, (ii) mitoribosomes, and (iii) mtDNA nucleoids are the main
cellular consequences of ClpP absence. However, the sequence of these events and their validity in
human remain unclear. Here, we studied global proteome profiles to define ClpP substrates among
mitochondrial ClpX interactors, which accumulated consistently in ClpP-null mouse embryonal
fibroblasts and brains. Validation work included novel ClpP-mutant patient fibroblast proteomics.
ClpX co-accumulated in mitochondria with the nucleoid component POLDIP2, the mitochondrial
poly(A) mRNA granule element LRPPRC, and tRNA processing factor GFM1 (in mouse, also GRSF1).
Only in mouse did accumulated ClpX, GFM1, and GRSF1 appear in nuclear fractions. Mitoribosomal
accumulation was minor. Consistent accumulations in murine and human fibroblasts also affected
multimerizing factors not known as ClpX interactors, namely, OAT, ASS1, ACADVL, STOM, PRDX3,
PC, MUT, ALDH2, PMPCB, UQCRC2, and ACADSB, but the impact on downstream metabolites
was marginal. Our data demonstrate the primary impact of ClpXP on the assembly of proteins with
nucleic acids and show nucleoid enlargement in human as a key consequence.
Keywords: leukodystrophy; ataxia; Parkinson’s disease; HARS2; LARS2; TWNK; ERAL1; ClpB
Cells 2021, 10, 3354. https://doi.org/10.3390/cells10123354 https://www.mdpi.com/journal/cells
Cells 2021, 10, 3354 2 of 29
1. Introduction
Primary ovarian insufficiency combined with early-onset sensorineural hearing loss,
inherited in an autosomal recessive manner, is the clinical hallmark of Perrault syndrome
(PRLTS). As underlying genetic causes, biallelic variants in the genes CLPP, HARS2, LARS2,
TWNK, ERAL1, GGPS1, PRORP, and HSD17B4 have been identified in 50% of cases, and
other putative disease genes are under investigation [1,2].
For accurate diagnosis and preventive therapy, it is important to understand what
subcellular compartments and pathways are disrupted in each genetic subtype of PRLTS,
and what crucial events are in common that lead to the selective pathology of Perrault syn-
drome. The disease-associated genes mostly encode mitochondrial proteins, with HARS2,
LARS2, and ERAL1 serving roles for mitoribosomal translation apparatus assembly [3],
while PRORP, HARS2, and LARS2 jointly function in tRNA processing of mitochondria [4].
The TWNK gene product Twinkle is well characterized as a helicase and primase for mito-
chondrial DNA, and mitochondrial RNA granules were recently found to need it [5], but
no mitoribosomal function has been described to date. Interestingly, one Twinkle isoform is
targeted to the nucleus and localizes to the kinetochore during progenitor cell division [6],
a fact that might relate to the primary oocyte failure in Perrault syndrome. An apparently
unrelated localization and function is known for the GGPS1 gene product Geranylgeranyl
Diphosphate Synthase 1, a cytosolic key enzyme for carotenoid biosynthesis, for the C20
prenylation of proteins, and for the regulation of a nuclear hormone receptor [7].
A wider spectrum of targets was described for the mitochondrial matrix peptidase
ClpP, which plays important roles during the unfolded protein response for mitochondria
(UPRmt) [8,9]. It depends on AAA+ ATPases such as ClpX for activation, substrate selection,
and disaggregation, thus converting into a protease [10–12]. Two heptameric ClpP rings
assemble with hexameric ClpX rings on either side into a barrel-shaped unfolding and
degradation machine [13]. In contrast, ClpB, as another member of the Clp/Hsp100 AAA+
ATPase family, acts to disaggregate proteins in concert with the cognate DnaK/Hsp70
chaperone system, without associating with ClpP or activating degradation [14]. Ho-
mozygous deletion of ClpP in mouse was found to trigger accumulated levels of the
disaggregase ClpX, mitoribosomes, and mitochondrial nucleoids [15–17], but it remains
unclear whether this pathology exists in human and which event is primary. Whether the
ClpP-null-triggered, on average 1.3-fold accumulation of mitoribosomal proteins depends
on the RNA chaperone ERAL1 or other factors also remains under debate [16,18]. ClpP
deficiency in mouse also causes reduced body size with leanness, even before the manifes-
tation of complete infertility and hearing impairment [15,19,20]. Interestingly, ClpP-mutant
mice and patients affected by Perrault syndrome type 3 (PRLTS3) display not only primary
ovarian insufficiency, as in other forms of PRLTS, but also azoospermia [15,21], indicating
that germ cell differentiation and meiosis have profound defects, while mitotic prolifer-
ation rates of ClpP-null mouse cells appear normal. The PRLTS3 infertility is complete,
a phenotype much stronger than the asthenozoospermia usually observed in mitochon-
drial disorders [22], suggesting that severe extra-mitochondrial pathology may contribute
to PRLTS3.
The existence of retrograde signaling about mitochondrial needs and problems to the
nucleus has been well established; in particular, the communication via calcium release
and endoplasmic reticulum signals are well understood [23]. How UPRmt is sensed and ex-
ecuted in the nucleus can apparently be mediated by a host of differing mechanisms across
phyla [24]. In the age-associated neurodegenerative disorder known as Parkinson’s disease,
pathogenic variants of the mitochondrial membrane factor CHCHD2 were shown to stimu-
late UPRmt via CHCHD2 nuclear relocalization and via CHCHD10 oligomerization [25–27].
As a main nuclear transcriptional response to ClpP-null-associated mitochondrial pathol-
ogy in mice, a massive induction of innate immunity factors was documented, triggered
by mtDNA and mitoribosomal stress via the cGAS-STING signaling pathway, and by the
nuclear accumulation of the co-chaperone DNAJA3 [17,28–30]. Again, it is unclear if such
neuroinflammatory events underlie the PRLTS3 neurodegenerative process in humans.
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Here, the identification of initial events of pathogenesis was achieved by a multi-
layered approach: The consistency of ClpP-dependent protein accumulations was assessed
in global proteome profiles from mouse embryonal fibroblasts (MEFs), mouse brain frac-
tions, and skin fibroblasts from patients with biallelic ClpP variants. This approach was
conducted under the assumption that the comparison of fibroblasts (where energy is
mainly generated by glycolysis and the downstream mitochondrial Krebs cycle) versus
brain tissue (where energy is mainly generated via mitochondrial respiration) would help
to define the invariant key ClpXP substrates. We classified accumulated mitochondrial
proteins according to evidence if (i) they are bona fide interactors of the disaggregase ClpX,
(ii) targets of the disaggregase ClpB, (iii) protein interactors of ClpP itself, or (iv) rather
may represent indirect effects due to delayed protein complex turnover and inefficient
assembly that are consequences of altered chaperone abundance. The degree to which such
misassembly of matrix enzymes impacts mitochondrial function was studied by mouse
fibroblast metabolome mass spectrometry and from a literature review (scheme in Figure 1).
Immunoblots of putative ClpP substrates in subcellular fractions assessed if excess amounts
of ClpX and its interactors associate with docking sites outside mitochondria. The find-
ings provide prominent novel insights into how ClpP inactivity has an early preferential
ClpX-dependent impact on tRNA processing factors of mitochondria (and possibly the
nucleus). As variants in other tRNA processing factors such as PRORP, HARS2, and LARS2
are a known cause of PRLTS, a common mechanism of disease pathogenesis begins to
emerge for Perrault syndrome. In addition, consistent accumulations that are potentially
independent of ClpX were observed for specific vitamin-associated multimerized factors
in the mitochondrial matrix.
Figure 1. Schematic overview of experimental setup and main findings. Numbers represent amount
of dysregulated factors, red arrows pointing up indicate significant upregulations, and blue arrows
pointing down indicate downregulations. Number of biological replicates (different cell lines or mice)
is represented by non-overlapping symbols, and cell line triplicates are shown as overlapping.
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2. Materials and Methods
2.1. Mice
ClpP-null mice had been generated previously [15], were bred from heterozygous
matings, and were housed under specific-pathogen-free conditions with monthly testing of
sentinel animals, using a 12 h light cycle with food and water ad libitum in the central animal
facility (ZFE) at Frankfurt University Hospital. All animal experiments were performed in
compliance with the German animal welfare law.
2.2. MEF Generation and Culture
Generation and cell culture of mouse embryonic fibroblasts (MEFs) were conducted
as previously described [29]. After intercrosses of ClpP+/− mice, WT and ClpP−/− MEFs
were prepared from embryos at 14.5 days post-coitus. Cells were grown in Dulbecco’s
modified Eagle medium (DMEM) (Gibco, Thermo Fisher Scientific, Waltham, MA, USA)
supplemented with 1% L-glutamine (Gibco, Thermo Fisher Scientific) and 10% fetal bovine
serum (FBS) (Gibco, Thermo Fisher Scientific) in a humidified incubator at 37 ◦C and
5% CO2.
2.3. Label-Free Quantification of Proteins in Wild-Type and ClpP-Null Mouse
Embryonic Fibroblasts
The mass spectrometry proteomics data were deposited in the ProteomeXchange
Consortium (http://www.proteomexchange.org/, last accessed on 26 November 2021) via
the PRIDE [31] partner repository with the dataset identifier PXD023677. Details of sample
preparation, quantitative mass spectrometry, and protein identification/quantification are
also available in PXD023677. Identifications from the reverse decoy database, by site and
known contaminants, were excluded. Data were further bioinformatically analyzed by
Perseus 1.5.2.6, (Max-Planck-Institute for Biochemistry, 80539 München, Germany) [32]
and Microsoft Excel, (version 2016, Redmont, WA, USA). For quantification, proteins
were quality filtered according to a minimum of 3 valid values in 1 group (n = 3). All
missing values from this reduced matrix were replaced by background values from a
normal distribution. For statistical comparison, Student’s t-tests were used. Quantification
results are summarized in tables. Data were visualized by volcano plots to highlight the
most significant hits. Heatmaps, volcano plots, and correlation profiles were generated by
Perseus 1.5.2.6.
2.4. Sequential Proteome Analysis of Clp−/− versus WT Mouse Brain Tissue
Female 15-month-old WT and age-matched ClpP−/− (n = 6 versus 6) mice were
sacrificed by decapitation. Their brains were dissected and snap frozen in liquid nitrogen.
Frozen brain samples were homogenized in ice-cold buffer (150 mM NaCl, 0.5 mM EDTA,
100 mM Tris pH 7.4) using a motor-driven Potter–Elvehjem with 15 strokes. Samples
were further sonified with 10 pulses. Following centrifugation at 16,000 rpm for 10 min
at 4 ◦C, the supernatant was transferred to a new tube and precipitated with 20% TCA.
The pellet was resolved in extraction buffer (10% SDS, 150 mM NaCl, 50 mM HEPES pH
7.8). Precipitated proteins were washed twice with ice-cold acetone and finally resolved in
extraction buffer. Sonification for 5 s facilitated resolubilization of proteins. An amount of
100 µg of protein from each fraction was diluted in 4% (w/v) SDS, 100 mM HEPES, pH 7.6,
150 mM NaCl, 0.1 M DTT, mixed with 200 µL 8 M Urea, 50 mM Tris/HCl, pH 8.5, and
loaded to spin filters with a 30 kDa cut-off (Microcon, Burlington, MA, United States). The
filter-aided sample preparation protocol (FASP) [33] was essentially followed. Proteins were
digested overnight with trypsin/LysC (sequencing grade, Promega, Madison, WI, United
States). Following established protocols [34], acidified peptides (final concentration 0.1%
v/v trifluoroacetic acid) were fractionated on multi-stop-and-go tips (StageTips, Thermo
Fisher Scientific, Waltham, MA, USA) containing C18 tips and strong cation exchange
(SCX) tips. Peptides from the pellet fraction were eluted in 3 steps. The C18 translution
fraction was combined with the first SXC fraction as well as the second and third SCX
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fractions. Peptides from the supernatant fraction were eluted in 6 steps. All fractions of
each sample were eluted in wells of microtiter plates. Peptides were dried and resolved in
1% acetonitrile, 0.1% formic acid.
Liquid chromatography/mass spectrometry (LC/MS) was performed on a Thermo
Scientific™ Q Exactive Plus equipped with an ultra-high performance liquid chromato-
graphy unit (Thermo Scientific EASY- nLC) and a Nanospray Flex Ion-Source (Thermo
Scientific, Waltham, MA, USA). Peptides were loaded on a C18 reversed-phase precolumn
(Thermo Scientific) followed by separation on a 2.4 µm Reprosil C18 resin (Dr. Maisch
GmbH, Ammerbuch, Germany) in-house packed picotip emitter tip (diameter 75 µm, 30 cm
long from New Objectives, Aarle-Rixtel, Netherlands) using a gradient from mobile phase
A (4% acetonitrile, 0.1% formic acid) to 30% mobile phase B (80% acetonitrile, 0.1% formic
acid) for 75 min followed by a second gradient to 60% B for another 30 min with a flow
rate 250 nL/min. The run was finished by column washout with 99% B for 5 min and
re-equilibration in 1% B.
Xcalibur Raw files were analyzed by proteomics software Max Quant (1.5.3.30, München,
Germany) [35]. The enzyme specificity was set to Trypsin, and missed cleavages were limited
to 2. Acetylation of the N-terminus (+42.01) and oxidation of methionine (+15.99) were selected
for variable modification, and carbamidomethylation (+57.02) on cysteines was set as a fixed
modification. The mouse proteome set from Uniprot (Download 26 February 2016) was used
to identify peptides and proteins. The false discovery rate (FDR) was set to 1%. Label-free
quantification values were obtained from at least one identified peptide. Identifications from
the reverse decoy database, by site and known contaminants, were excluded. Data were further
bioinformatically analyzed by Perseus 1.5.2.6. (http://coxdocs.org/doku.php?id=perseus:
start, accessed on 8 March 2021) and Microsoft Excel. For quantification, proteins were
quality filtered according to a minimum of five valid values in one group (while total sample
number n = 6). All missing values from this reduced matrix were replaced by background
values from a normal distribution. For statistical comparison, Student’s t-tests were used.
Quantification results are summarized in tables. Data were visualized by volcano plots to
highlight the most significant hits. Heatmaps, volcano plots, and correlation profiles were
generated by Perseus 1.5.2.6. Pathway analysis was conducted by DAVID Bioinformatics
Resources 6.7 (Frederick, MD, USA), GOrilla GO [36], and KEGG (Kyoto Encyclopedia of
Genes and Genomes) pathway analysis.
2.5. Metabolome
For the quantification of 54 metabolic compounds in MEFs, 100 mg cell pellets
(1 × 107 cells per line, for 8 WT versus 8 ClpP−/−) were snap frozen in liquid nitrogen,
stored at −80 ◦C, and shipped on dry ice to the company Metabolomic Discoveries (Pots-
dam, Germany). Targeted profiling with unambiguous characterization and relative quan-
tification by LC-tandem mass spectrometry was performed on a Shimadzu (Kyoto, Japan)
triple quadrupole LCMS-8050 equipped with an electrospray ionization (ESI) source and
operated in multiple reaction mode (MRM). For statistical evaluation, raw data as peak
abundances normalized to internal standards and, if necessary, protein content were de-
tailed, complemented by means and standard deviation values, as well as a differential
analysis sheet with ANOVA across all groups as a global p-value, and an adjusted global
p-value, followed by a local p-value from pairwise t-tests and ratios of the group means as
a log2 value, as well as absolute fold changes. Absolute numbers were normalized against
the mean of WT samples. Bar graphs were created with GraphPad Prism (GraphPad
Software, San Diego, CA, USA) version 9.
2.6. Quantitative Immunoblots
Protein was isolated with RIPA buffer (50 M TRIS/HCl pH 8.0, 150 mM NaCl, 0.1%
SDS, 1% triton, 0.5% sodium deoxycholate, 2 mM EDTA, protease inhibitor cocktail (Sigma
Aldrich, St. Louis, MI, USA)) as previously described [15]. Protein content was determined
using BCA assay (Life Technologies, Carlsbad, CA, USA). An amount of 15 µg of protein
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was loaded for quantitative immunoblotting. Subcellular fractions were done as previously
published [29]. Antibodies used were against HSP60 (SantaCruz (Dallas, TX, USA) sc-13115;
1:500), Lamin A/C (Abcam (Cambridge, UK), ab169532; 1:1000), GAPDH (Calbiochem
(Merck Millipore, Darmstadt, Germany), CB1001; 1:1000), CLPX (murine: Invitrogen
(Waltham, MA, USA), PA5-79052; 1:1000; human: Sigma Aldrich, HPA040262; 1:1000),
POLDIP2 (Proteintech (Manchester, UK), 15080-1-AP; 1:1000), LRPPRC (Invitrogen, PA5-
22034; 1:1000), GRSF1 (Sigma Aldrich, HPA036985; 1:1000), GFM1 (Proteintech, 14274-1-AP;
1:1000), CHCHD2 (Proteintech, 19424-1-AP; 1:1000), OAT (Invitrogen, PA5-92842; 1:1000),
and MUT (Proteintech, 17034-1-AP; 1:1000).
2.7. Human Primary Skin Fibroblasts
Skin cells were donated by a 33-year-old male Arabic individual with a homozygous
ClpP mutation (c.[430T>C]; p.[Cys144Arg]; ID-number CB16-0006) who was diagnosed
with bilateral sensorineural hearing loss at 14 months of age [21]. The deafness has contin-
uously progressed since. He developed foot drop at 24 years of age with sensory-motor
demyelinating axonal peripheral neuropathy of the lower limbs upon neurophysiological
testing. In adulthood, he was shown to have azoospermia.
Further skin cells became available from a 4-year-old female Turkish individual with
a homozygous ClpP mutation (c.[661G>A]; ID-number 58955) leading to open reading
frameshift and undetectable ClpP protein in fibroblast immunoblots [37]. This patient in
the first week of life already had muscular weakness. At age 2 months, she was diagnosed
with microcephaly (1 cm < 3rd percentile) and showed generalized muscular hypotonia.
Echocardiography demonstrated mild hypertrophic cardiomyopathy. Metabolic analysis
disclosed repeatedly metabolic acidosis with elevated lactate levels (2.8 to 9.0 mmol/L,
normal <2.3 mmol/L). Fumaric acid, 2-oxo-glutaric acid, and methylmalonic acid were
mildly elevated in her urine. Respiratory complex III and IV activity were reduced in
muscle biopsy [37]. Subsequently, progressive developmental delay and deafness became
evident. She developed epilepsy (West syndrome). At the time of skin biopsy, she was
5 years of age.
For comparison, primary skin fibroblast cultures from the Coriell depository (lines
AG06103, AG02261, and AG06858) and other cultures from healthy controls kindly pro-
vided by Prof. Henry Houlden (UCLH, London, UK) (4 cases) were studied. Cell lines were
cultivated in DMEM (Gibco, Thermo Fisher Scientific) supplemented with 1% L-glutamine
(Gibco) and 10% fetal bovine serum (FBS) (Gibco, Waltham, MA, USA) in a humidified
incubator at 37 ◦C and 5% CO2. This study was conducted according to the guidelines of
the Declaration of Helsinki and approved by the Ethics Committee of Klinikum Goethe
Universität Frankfurt/Main (protocol code 117/07, 24 May 2007) and the Wales Research
Ethics Committee (protocol code 16/WA/0017 and original approval, 4 February 2016).
2.8. Polymerase Chain Reaction (PCR) to Control for Mycoplasma Contamination
Here, 200 µL cell culture media from cultures that had grown for at least 48 h were
collected and boiled for 5 min at 95 ◦C. Samples were centrifuged for 2 min at maximum
speed. The PCR reaction mix contained 1 µL sample, 7.4 µL water, 0.8 µL primer forward,








and reverse primers contained
Myco-3-1 GCGGTGTGTACAAGACCCGA,
Myco-3-2 GCGGTGTGTACAAAACCCGA,
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Myco-3-3 GCGGTGTGTACAAACCCCGA.
Each primer was dissolved to a final concentration of 100 µM, and forward and reverse
were mixed to a final concentration of 10 µM each. PCR was conducted at the following
times and temperatures: 95 ◦C for 5 min, (95 ◦C for 15 s, 56 ◦C for 15 s, 72 ◦C for 30 s) × 40,
72 ◦C for 3 min. Samples were run on a 1.5% agarose gel (agarose: Thermo Fisher Scientific).
2.9. Global Proteome of Human Fibroblasts
Seven control subject cell lines and the two PRLTS3 patient cell lines (in triplicates)
were cultured in T75 flasks, washed with PBS (Gibco), and lysed with trypsin (Gibco).
The lysates were centrifuged and resuspended in 150 µL lysis buffer (50 mM Tris pH 7.5,
150 mM NaCl, 1% NP40, 0.1% sodium deoxycholate, 1 mM EDTA, and protease inhibitor).
Protein content was determined using BCA assay (Life Technologies). An amount of 300 µg
of each sample was precipitated according to the method of Wessel and Flügge [38], and
the proteins were resuspended in 8 M Urea for denaturation. Samples were loaded on
molecular cut-off spin columns (Microcon 30 kDa, Merck Millipore) and subsequently
reduced, alkylated, and digested with trypsin on the filters following the FASP protocol
described by Wiśniewski et al. [33]. The obtained peptide mixtures were lyophilized,
desalted on 50 mg SepPac C18 columns (Waters), and afterwards fractionated on self-made
SCX stage tips (3 disks of SCX material, Empore, Sigma Aldrich, St. Louis, MI, USA, in
200 µL pipette tips). Peptides bound to the SCX material were stepwise eluted with five
different concentrations of AcONH4 (20 mM, 50 mM, 100 mM, 250 mM, and 500 mM),
0.1% TFA, 15% acetonitrile. Overall, 65 samples (5 fractions for each of the 13 fibroblast
culture samples) were further lyophilized, desalted on self-made C18 stage tips (2 layers of
C18 disks, Empore), and, after final lyophilization, resuspended in 25 µL 0.1% formic acid
(FA) and filtered through equilibrated 0.2 µm Millipore filters before mass spectrometry
(MS) measurement.
Nanoflow liquid chromatography-MS/MS analysis was performed on an Orbitrap
Fusion mass spectrometer (Thermo Fisher) coupled to an UltiMate 3000 Nano HPLC system
(Thermo Fisher). Peptides were first loaded on a C18 Acclaim PepMap100 trap column
(75 µm ID × 2 cm) and then separated on an Aurora UHPLC analytical column, 75 µm ID
× 25 cm, 120 Å pore size (Ionopticks, Fitzroy, Australia). Columns were constantly heated
at 40 ◦C. Subsequent separation was performed using a first gradient ranging from 5 to
22% acetonitrile in 0.1% FA for 105 min followed by a second gradient ranging from 22 to
32% acetonitrile in 0.1% FA for 10 min at an overall flow rate of 400 nL/min. Peptides were
ionized via electrospray ionization. Measurements on the Orbitrap Fusion were carried out
in a top speed data-dependent mode using a cycle time of 3 s. Full scan (MS1) acquisition
(scan range of 300–1500 m/z) was performed in the Orbitrap at a defined resolution of
120,000, with an automatic gain control (AGC) ion target value of 2e5, whereby dynamic
exclusion was set to 60 s. For fragmentation, precursors with a charge state of 2–7 and a
minimum intensity of 5e3 were selected and isolated in the quadrupole using a window of
1.6 m/z. Subsequent fragment generation was achieved using higher-energy collisional
dissociation (HCD, collision energy: 30%). The MS2 AGC was adjusted to 1e4, and 35 ms
was selected as the maximum injection time for the ion trap (with inject ions for all available
parallelized times enabled). Scanning of fragments was performed by applying the rapid
scan rate.
MS Bioinformatics: MS raw files were analyzed with MaxQuant software (version
2.0.3.0, München, Germany). The search was based on the Uniprot human reference protein
database downloaded on 10 October 2021, containing 20,371 entries. Most default settings
of MaxQuant were applied: PSM and protein FDR 1%; enzyme specificity trypsin/P;
minimal peptide length: 7; variable modifications: methionine oxidation, N-terminal acety-
lation; fixed modification: carbamidomethylation. For protein identification, the minimal
number of unique peptides was set to 2. The match between runs option was enabled. For
label-free protein quantification, the MaxLFQ algorithm was used as part of the MaxQuant
environment: (LFQ) minimum ratio count: 2; peptides for quantification: unique. Statisti-
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cal analysis was performed in Perseus (version 1.6.15.0, accessed on 29 September 2021).
Proteins identified only by site, reverse hits, or potential contaminants were removed. LFQ
intensities were log2 transformed. Samples were grouped into two categories: control
(7 samples) and PRLTS3 (3 samples for patient 0006, plus 3 samples for patient 58955),
and then filtered for at least four valid values in each group. The replicate groups were
compared via a two-sided, two-sample Student’s t-test (S0 = 0, permutation-based FDR
method with FDR = 0.05 and 250 randomizations).
2.10. Immunofluorescence
Human fibroblasts were grown on 12 mm coverslips 16 h before experiments. The
next day, cells were washed with PBS, fixed with 4% paraformaldehyde for 20 min, perme-
abilized with 0.1% Triton X-100 in PBS for 5 min, and blocked with PBS containing 10%
FBS for 30 min. After blocking, cells were incubated with primary antibodies for 60 min
and stained with secondary antibodies for 60 min. Cells were washed with PBS between
each step. Coverslips were mounted with Prolong Gold anti-fade reagent containing DAPI
(Molecular Probes, Eugene, OR, USA). Images were collected with a Nikon Eclipse Ti2
inverted microscope using a 60X oil-immersion objective and NIS-Elements Advanced
Research software, version 5.21.02 (Amsterdam, The Netherlands). Z-stack images were
processed using the NIS Extended Depth of Focus module to create focused, single-plane
maximum intensity projection TIFs. Nucleoid area quantification was performed largely
as described [17]. Briefly, approximately 3–4 unique fields of view from 3 distinct images
(of each genotyping at each treatment) comprising between 800 and 1000 nucleoids were
captured at random. Scale information was added to Image J (Bethesda, MD, USA), then
images were made binary, and the area of each nucleoid was determined using the ‘An-
alyze Particles’ feature of ImageJ. Nucleoids were divided into 2 size cut-offs: <150 nm2
and ≥150 nm2, and values were plotted as percentage (%). The following antibodies
were employed: anti-TFAM (Proteintech (Manchester, UK), 23996-1-AP; 1:200), anti-HSP60
(Santa Cruz, (Dallas, TX, USA), sc-1052; 1:300), anti-ClpP (Proteintech (Manchester, UK),
60004-1-LG; 1:200), anti-DNA (Millipore (Darmstadt, Germany), CBL-186 AC-30-10; 1:300).
2.11. Quantitative Polymerase Chain Reaction (qPCR)
Total cellular DNA was isolated with 250 µL (12-well plate) of 50 mM NaOH and
boiled for 30 min to solubilize DNA. An amount of 25 mL of 1 M Tris-HCl pH 8 was
added to neutralize the pH, and DNA was quantified and diluted to obtain a 2 ng/µL
concentration. DNA was then subjected to qPCR using Fast SYBR Green Master Mix
(Applied Biosystems, Waltham, MA, USA) and primers indicated below. Three technical
replicates were performed for each biological sample, and expression values of each
replicate were normalized against KIR4 using the 2−∆ddCt method. Results were plotted as











2.12. Reverse Transcriptase Quantitative Real-Time Polymerase Chain Reactions (RT-qPCRs)
Total RNA from snap-frozen cell pellets (n = 4 WT versus 4 ClpP−/− MEF lines) was
isolated with TRI reagent (Sigma, Burlington, MA, USA). DNase (Amplification Grade,
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Invitrogen) was used for purification of RNA, and SuperScript III (Invitrogen) for reverse
transcription, following manufacturers’ instructions. qPCR was performed with TaqMan
Gene Expression Assays (Applied Biosystems) in cDNA from 20 ng total RNA in 20 µL
reactions with 2× master mix from Roche in a StepOnePlus Real-Time PCR System (Ap-
plied Biosystems, Waltham, MA, USA). The analysis of the data was carried out with the
2−∆∆CT method [39]. The following Taqman assays (ThermoFisher, Waltham, MA, USA)
were employed for murine transcripts: ClpP: Mm00489940_m1, ClpX: Mm00488586_m1,
Poldip2: Mm00458936_m1, Lrpprc: Mm00511512_m1, Grsf1: Mm00618579_m1, Gfm1:
Mm00506856_m1, Chchd2: Mm01742631_s1, Mut: Mm00485312_m1, Oat: Mm00497544_m1,
Tbp: Mm00446973_m1.
2.13. Bioinformatic Analyses
Global proteome Perseus output data were further analyzed employing the STRING
webserver (https://string-db.org/, last accessed on 1 July 2021) for protein–protein in-
teraction and pathway analyses. Filtered gene symbols were entered into the Multiple
Proteins option for Mus musculus, and the graphical output was archived, highlighting
factors with identical features by coloring, as explained in figure captions. Significant
enrichments of GO (Gene Ontology) terms and KEGG pathways were exported into Excel
files. For further protein interaction studies, the biomedical interaction repository BioGrid
(https://thebiogrid.org/, last accessed on 6 September 2021) was used. The interactors
for human ClpP, ClpX, and ClpB were searched independently, and the BioGRID output
data were saved as Excel files. Data were manually filtered for non-redundant factors in
separate work sheets, and proteins were matched with global proteome data. Overlapping
proteins between different datasets were identified by creating Venn diagrams using the
website http://bioinformatics.psb.ugent.be/webtools/Venn/, last accessed on 11 Septem-
ber 2021. An overview of Venn output data is included in Figure 1. Fisher’s exact test
implemented in Perseus was used to identify non-random associations between terms
in categorical columns. Tables include t-test p-values and the Benjamini–Hochberg FDR
(multiple hypothesis testing). Statistical evaluation was conducted using GraphPad Prism
version 9. Bar graphs show variances as the standard error of the mean (SEM) and p-values
from Welch’s t-test (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001).
3. Results
3.1. ClpP-Null MEF Proteome Profile and Its Bioinformatic Analysis
We aimed to identify ClpP-dependent protein degradation deficits, and to define a
sequence of events within mitochondria to elucidate the initial events in PRLTS3 pathogen-
esis. Primary fibroblasts were prioritized since they are easily available from ClpP-mutant
patient skin and from mouse embryos. Cultures of three ClpP-null versus three age-
/sex-matched WT MEFs were extracted with 10% SDS and analyzed with label-free mass
spectrometry to survey alterations in protein abundance. Among 5838 detected factors
(Table S1 complete with imputation), 436 were significantly decreased, while 235 showed
significantly increased levels. Preferential mitochondrial localization is known for 26 down-
regulated and 63 upregulated factors (Table 1). Putative ClpP-dependent degradation
substrates would be expected among the latter ones. The absence of ClpP and the previ-
ously reported accumulation of its substrate-selecting interactor ClpX [15] were confirmed
in the mass spectrometry spectra.
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Table 1. Mitochondrial proteins (UniProt-IDs) with significant downregulation (upper part) and upregulation (lower part)
in ClpP-null MEFs versus WT (3 versus 3). Factors with special relevance for this manuscript are highlighted in bold letters.
Previously reported candidate ClpP cleavage substrates in mouse are identified at the right margin with citations of the
relevant PubMed-ID number.
Downregulations
Majority Protein IDs Gene Names p-Value Fold Changewith Imputation
Q8BWT1;Q3UKH3 Acaa2 0.0009 −1.23
Q8JZN5 Acad9 0.0024 −1.26
F6 × 5P5;Q6PE15 Abhd10 0.0029 −1.98
Q64429;Q80V82;Q3UTK2;Q9CUA1;Q8BRY0 Cyp1b1 0.0047 −6.59
P32020 Scp2 0.0048 −1.31
Q3UGW4;O88696;Q8CF81 Clpp 0.0065 −14.78
Q3V471;Q8C253;P16110 Lgals3 0.0077 −1.18
O08528;E9Q5B5 Hk2 0.0098 −1.34
Q923F9;E9QPX3;Q9CXZ1;Q9CTT4 Ndufs4 0.0119 −1.26
Q9CRB9;S4R238;Q9D9P1;D3Z0L4;Q91VG6 Chchd3 0.0161 −1.14
Q91YP2;Q3UUI1;Q3TB65 Nln 0.0186 −1.30
Q9CQ54;Q9D846 Ndufc2 0.0194 −1.28
P48771 Cox7a2 0.0195 −2.71
Q9Z2I8;C6EQH3 Suclg2 0.0206 −1.44
Q9CQB5;D3Z3X4 Cisd2 0.0211 −1.23
Q6GQU1;Q3UPC4;Q3TJE3;G3UVV4;P17710;Q3UE51;Q3TTB4 Hk1 0.0218 −1.11
X2EXD0;Q920L1 Fads1 0.0226 −1.44
A0A0R4J0G0;Q8BH04;Q8R3X7;Q3UGF0 Pck2 0.0304 −1.20
Q9CS68;Q9WV84 Nme4 0.032 −1.55
Q8BH95;F6T930 Echs1 0.0352 −1.23
Q9CYT3;Q99N15;A2AFQ2;O08756 Hsd17b10 0.0374 −1.21
A2AP32;A2AP31;Q3UIU2 Ndufb6 0.042 −1.42
Q9WTP7;Q9D8W6 Ak3 0.0423 −1.13
Q9D6U8 Fam162a 0.0427 −1.36
Q9D0K2;Q3UK61;Q3U9P7;Q3UJQ9;Q9CRF4 Oxct1 0.0475 −1.20
Q8K009;D3Z6B9 Aldh1l2 0.0496 −1.38
Upregulations
Majority Protein IDs Gene Names p-Value Fold Changewith Imputation
Previous Mammalian
Substrates PMID
P38647 Hspa9 2E-07 1.41 32467259
E9Q179;Q8C5Q4;Q8C298 Grsf1 3E-05 4.64
Q60597;Z4YJV4 Ogdh 9E-05 1.16
O35459;F7B227 Ech1 1E-04 2.35
Q8CCC0;Q3TZ21;Q9DCJ7 Aurkaip1 0.0003 3.20
Q8K0D5 Gfm1 0.0003 2.62
F6SQH7;Q91VA6 Poldip2 0.0003 2.08 32467259
Q3UJ34;Q3UEJ7;P16460;J3QNG0 Ass1 0.0005 1.80
A0A0M3HEP3;Q8CCZ4;D3Z6I3;Q99M04 Lias 0.0008 4.07
Q8C6I2 Sdhaf2 0.0009 7.70
Q3TG75;P29758;Q3UKT3;Q3UJK5 Oat 0.0012 2.09 32467259
Q9DB77 Uqcrc2 0.0013 1.48
Q3TJA9;Q99M87 Dnaja3 0.0016 2.33
F7ASG0;Q9CWV0 Malsu1 0.0017 4.73
Q8CC88 Vwa8 0.002 1.74
A0A0A0MQD1;Q8K1H1 Tdrd7 0.0023 1.51
Q8BK72;Q80ZI4 Mrps27 0.0024 1.72
Q6PB66 Lrpprc 0.0027 1.33
Q3TIC8;Q9CZ13;Q3THM1;Q8K2S8 Uqcrc1 0.0033 1.65 32467259
Q7TMY2;Q9DBL1;E9Q5L3;Q3V2R9 Acadsb 0.0033 1.33
Q3TI14;Q99LZ4;Q8VE22;F7ARZ1;A7M7Q8;Q3THH3 Mrps23 0.0034 1.67
Q8K2B3 Sdha 0.0036 1.36
P20108 Prdx3 0.0039 1.29
Q3UCB5;Q3UC13;O55028;Q8C6H9;D3Z7R0;Q99KP1 Bckdk 0.0053 3.98
Q61102 Abcb7 0.0066 1.62
Q99N96;Q9D3F3;Q9CUL8 Mrpl1 0.0066 1.60
Q922Z3;Q3UPJ8;Q9CQN1;Q922R9;Q3TK29;Q3TSG8 Trap1 0.0074 1.62
Q3URE1 Acsf3 0.0074 1.25
Q9CQE3;D3Z198;D3YWF8 Mrps17 0.0079 1.75
Q99LP6 Grpel1 0.0081 1.67
Q9D7N3;Q3UMV5;Q9ER89;Q5XJX8 Mrps9 0.0093 1.58
Q810B1;Q6P060;Q5RL20;Q99N89 Mrpl43 0.0097 2.64
P18155;Q3U8E7 Mthfd2 0.0131 2.80
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Table 1. Cont.
Downregulations
Majority Protein IDs Gene Names p-Value Fold Changewith Imputation
P16332;Q8VED0 Mut 0.0135 1.37
Q3UTB8 Grpel1 0.0136 3.26
Q544B1;Q3UJW1;Q3U9J7;P47738;A0A0G2JEU1;Q3U6I3;Q3TVM2 Aldh2 0.014 1.53
Q3TPD9;Q3U2X5;Q64133;Q3UJ53 Maoa 0.0164 1.17
G5E8R3;Q3T9S7;E9QPD7;Q3TCQ3;Q05920;Q3UFS6;Q62043;Q8BP54 Pcx;Pc 0.0165 1.27
Q80X85 Mrps7 0.0173 1.26
Q3U9C4;Q3UKG1;Q9CY73 Mrpl44 0.0185 1.41
D3Z5B1;Q8CEW7;B2RPU8;Q9D1L0 Zbed5;Chchd2 0.0193 1.47
Q9JK42 Pdk2 0.0212 1.72
Q9CQ06 Mrpl24 0.0216 2.08
Q3TFD0;Q9CZN7;Q99K87 Shmt2 0.0217 1.21
E9Q0A7;Q4KMM3 Oxr1 0.022 1.37
Q9CXW2 Mrps22 0.0236 1.87
A0A0N4SUH8;Q9QZ23 Nfu1 0.025 1.58
E0CX98;Q9D2C7;E0CZE8;E0CXR0 Tmbim6 0.0251 1.71
Q6P8N8;Q9JHS4 Clpx 0.0296 1.77
Q545U2;Q9Z0V8;D3Z1Z0 Timm17a 0.0296 1.29
Q9CQ40;Q8BTB8 Mrpl49 0.03 1.25
Q9JKF7;Q8CCX9 Mrpl39 0.0305 3.35
Q9CXT8;Q3TET5 Pmpcb 0.0313 1.42
P50544;B1AR28;Q3UJR6 Acadvl 0.0313 1.23
B1B1D8;Q9D773 Mrpl2 0.0322 1.71
Q924T2;Q8BQ99 Mrps2 0.0327 1.65
Q9CQZ5 Ndufa6 0.0341 1.20
Q8BTQ6;Q9CQL5 Mrpl18 0.035 5.01
Q8BK51;A2AIW9;Q3UDE0;Q3TY06;Q3TTM6;Q9DC61 Pmpca 0.035 1.33
Q9D6Z0 Alkbh7 0.0351 5.84
Q545A2;P51881 Slc25a5 0.0355 1.22
Q8CG72 Adprhl2 0.0422 1.09
Q9DCB8 Isca2 0.0435 2.37
Q4FJR4;Q3V250;Q922H2 Pdk3 0.0445 1.96
Q7TMQ1;P23242 Gja1 0.0451 1.59
Imputation was performed to maximize the number of proteins under analysis, and
the power of subsequent bioinformatics. Evaluation of significant interaction clusters and
pathway enrichment among these factors employed the Fisher algorithm. This approach
revealed that the accumulations occurred mainly among extra-mitochondrial proteins of
the immune system and the extracellular matrix, while accumulated proteins in mitochon-
dria had a smaller number and amount of fold changes (most of them are known for a
role in the RNA metabolic process). In comparison, the reduced protein abundance was
clustered among nuclear proteins, particularly the spliceosomal complex (Table S1, further
datasheets). It was intriguing to note how mitochondrial ClpP inactivity affects nuclear
functions, but the mechanisms of this retrograde signaling require further elucidation. The
greater fold changes of extra-mitochondrial factors may be due to cytosolic signals being
amplified over many steps by orders of magnitude, as is known for phosphorylation and
blood coagulation cascades, and the strong inducibility of nuclear promoters (e.g., for
immediate-early genes) when there is no need to maintain stoichiometric ratios with mito-
chondrially encoded proteins. Thus, with largest effect sizes reflecting very downstream
events, we filtered by significance levels rather than fold changes in our subsequent quest
to identify primary events of pathogenesis.
In a more stringent analysis, we focused on those 169 proteins that were significantly
upregulated (p < 0.03) upon analysis without imputation. These potential ClpP substrates
were assessed on the STRING web platform, revealing a strongly significant protein–
protein interaction enrichment (p < 1 × 10−16). STRING generated a diagram of protein–
protein interactions that highlights a prominent network of mitoribosomal components and
molecular chaperones, as described [12,16]; in comparison, the assembly factors for iron–
sulfur cluster biosynthesis and respiratory chain elements as well as mitochondrial enzymes
played a minor role (Figure S1). The detailed analysis of enrichments (Table S2) also
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documented the previously reported increase in cytosolic innate immunity mediators [15],
and a novel elevation in secreted collagen precursors. Overall, the global proteome profiles
of ClpP-null MEFs were in excellent agreement with previous knowledge, but further
filtering was needed to identify ClpP substrates with a primary role in pathogenesis. It
remained unclear how to best eliminate the manifold downstream cell-wide effects.
3.2. Selected Dysregulations Are Reproducible in Brain Tissue and Reflect Direct ClpX Impact
on Interactors
Thus, we tested if these accumulations also occur in different cell fractions of female
15-month-old ClpP-null mouse brains. At this mouse stage, the cell stress of old age already
becomes apparent, while senescent multimorbidity has not yet begun. Sequential extrac-
tions from the brain tissue were performed, first obtaining readily solubilized proteins
with RIPA buffer, and subsequently solubilizing the resulting pellets in 2% SDS buffer to
also study the more insoluble proteins. After label-free mass spectrometric quantification
of individual peptides, the two resulting global proteome profiles from the brain extract
supernatant and pellet (Table S3) were compared with the initial data from complete MEFs
(Table S1). The significantly upregulated factors were filtered for consistency among all
lists, and for mitochondrial localization, producing a list of 37 potential ClpP degradation
substrates (Table S3). In the resulting STRING diagram (Figure 2) and pathway enrich-
ment statistics (Table S4), prominent accumulations of mitoribosomal proteins (blue color)
and chaperones were observed as before, and mitochondrial nucleoid factors became
more prominent (green), with most of these diagram nodes connected to ClpX accumu-
lation. Interestingly, several of the consistently upregulated factors localized not only to
mitochondria but, in parallel, also to the nucleus, particularly the nucleolus (Figure 2).
To act as a degrading protease, ClpP depends on ClpX for the selection and disaggre-
gation of its substrates, while ClpP, by itself, can only cleave small peptides. Thus, in our
reasoning, the accumulation of ClpX and its interactor proteins would be among the initial
primary events of pathogenesis in ClpP-mutant cells. To ensure that all available high-
quality data on endogenous protein complexes entered this analysis, the manually curated
BioGrid database entry on human ClpX protein associations was downloaded (Table S5).
Among these known ClpX interactors, the ClpP-null fibroblasts and brain tissues exhibited
consistent significant accumulations for the AAA+ ATPase ClpX itself, another AAA+
ATPase in mitochondria known as VWA8 (Von Willebrand Factor A Domain Containing
8) [40], the nucleoid component POLDIP2 (also known as PDIP38) (DNA Polymerase Delta
Interacting Protein 2) [41], the mitochondrial RNA granule component LRPPRC (Leucine
Rich Pentatricopeptide Repeat Containing) [42], the mitochondrial precursor RNA process-
ing factor GRSF1 (G-Rich RNA Sequence Binding Factor 1) [43], the mitoribosomal tRNA
translocation mediator GFM1 (G Elongation Factor Mitochondrial 1) [44], and the UPRmt
sensor CHCHD2 (Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 2) [25,45].
To assess the specificity of these observations, in comparison, we assessed the pro-
tein interaction list for the AAA+ ATPase ClpB, which is also conserved from bacte-
ria to mammalian mitochondria. Among the ClpB interactor proteins listed in BioGrid,
only three components of the small mitoribosomal subunit named MRPS9, MRPS22, and
MRPS27 showed consistent significantly upregulated abundance in ClpP-null MEFs and
brains (Table S5).
In a third BioGrid data mining effort, we looked into ClpP interactor proteins. Sig-
nificant accumulation in ClpP-null MEFs was observed for 37 such factors, among which
19 were also upregulated in ClpP-null brains (Table S5). Interestingly, only 6 of them are
known to associate with ClpP and with ClpX in parallel, but 13, and thus a majority, are
documented only as ClpP interactors, but not as ClpX interactors (e.g., OAT, ornithine
amino transferase). Naturally, such ClpX interaction may simply have been overlooked by
investigators focused on identifying ClpP substrates and might still be documented in the
future by more advanced methods. However, the frequency of this phenomenon made us
consider what the effects of ClpP activity would be when it is not associated with ClpX. It
is known (i) that the stoichiometric ratio between the peptidase ClpP and the disaggregase
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ClpX is not fixed between different tissues, (ii) that ClpX has some effects that are indepen-
dent from ClpP [46], and (iii) that the split of the ClpXP proteolytic digestion machinery
into two subunits contrasts with LonP1, where the substrate recognition/disaggregase
domain and the protease domain coexist within the same subunit (in complete conservation
across phyla). Thus, we subsequently assessed the possibility that ClpP deficiency might
lead to accumulation of cleavage substrates that do not interact with ClpX.
Figure 2. STRING protein–protein interaction diagram of significantly upregulated factors, consistent
among the global proteomes of MEFs, brain supernatants, and brain pellet fractions. The color of each
factor and the significance of enrichment are detailed above the diagram, showing its implication in
functional contexts. The color of lines between factors reflects the degree of known associations.
Overall, the additional proteomic work to define dysregulation consistency between
glycolytic fibroblasts and respiring brains, together with the filtering of dysregulated ClpX
protein interactors, permitted us to focus on fewer changes, which are possibly initial
events of pathogenesis and are clearly relevant for several cell types. These consistent
global proteome effects identified putative substrates, but they failed to clarify whether
impaired degradation or induced biosynthesis is responsible for the effects, and how the
mitochondrial pathology triggers the dysregulation of nuclear and nucleolar factors by
retrograde signaling.
3.3. Assessment of Transcriptional Induction
Therefore, we then assessed if these dysregulations are indeed due to altered protein
turnover, as a consequence of absent mitochondrial peptidase ClpP, or are due to secondary
transcriptional responses that represent compensatory or deleterious downstream events.
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Therefore, mRNA levels of these crucial factors were quantified by RT-qPCR and shown to
be unchanged, with the exception of ClpP mRNA absence (Figure 3). These data indicate
that the accumulation of these proteins is not due to nuclear transcriptional upregulation,
in agreement with the concept that the protein turnover rate of POLDIP2, LRPPRC, GRSF1,
GFM1, and CHCHD2 depends on ClpXP-mediated degradation.
Figure 3. Analyses of redistribution of mitochondrial factors to the nucleus. (A) Quantitative immunoblots were
used to control subcellular fractionation quality and loading by GAPDH, HSP60, or LAMIN A/C protein abundance.
(B) Immunoblot validation of protein accumulation in mitochondrial and nuclear fractions (membrane at left margin, bar
graph in center). (C) Assessment of underlying transcript levels by RT-qPCR (right margin) for specific ClpX interactors
in ClpP−/− (n = 3) versus WT (n = 3) mouse embryonal fibroblasts. * p < 0.05, ** p < 0.01; **** p < 0.0001; T represents
0.05 < p < 0.10.
Cells 2021, 10, 3354 15 of 29
3.4. Validation by Immunoblot, with Analysis of Subcellular Distribution
To validate the protein accumulations by quantitative Western blots, and to test
whether the ClpP deficiency triggers accumulation of these proteins only within mitochon-
dria or also extra-mitochondrially, subcellular fractionations of MEF cells by differential
detergent extraction were performed, as previously established [29]. Fractionation purity
was controlled by immunoblots with mitochondrial HSP60, cytosolic GAPDH, and nuclear
Lamin A-C, detecting no mitochondrial contamination in the nuclear fraction, and very
little nuclear material in the mitochondrial fraction; even the cytoplasmic contamination
was minor in these two fractions (Figure 3A).
As expected from the mass spectrometry data, the ClpX-immunoreactive band showed
accumulation, but unexpectedly, this effect was much stronger in the nuclear fraction than
in the mitochondrial fraction of MEFs (Figure 3B). This observation represents strong
evidence that ClpX selectively targets proteins that are associated with DNA or unspliced
RNA, so that excess ClpX amounts would find suitable docking sites mainly in the nucleus.
The analysis of the distribution of ClpX interactors POLDIP2 (predicted precursor size
42 kDa) and LRPPRC (predicted precursor size 158 kDa) showed their accumulations to be
restricted to mitochondria (Figure 3B).
In contrast, antibodies against GRSF1 (predicted precursor full-length size at 55 kDa)
and against GFM1 (predicted precursor size at 83 kDa) showed the expected band to
accumulate in mitochondria and the nucleus. The gain-of-function of the mRNA/tRNA/
rRNA/lncRNA processing factor GRSF1 and of the tRNA translocation mediator GFM1,
both in mitochondria and the nucleus, would probably contribute to mitoribosomal inef-
ficiency. Beyond mitochondrial translation, their excess may also alter nucleolar process-
ing/nuclear export, causing generalized cell stress.
The Parkinson’s disease (PD)-associated UPRmt sensor CHCHD2 (predicted precursor
size 16–18 kDa) was increased only in the mitochondrial fraction, and a slightly smaller
band in the nucleus did not show dysregulation. CHCHD2 is known to encode two
polypeptides, distinguished as PA and PB. The latter is shorter than PA due to the absence
of the putative mitochondrial targeting sequence [47]. An antibody of sufficient quality for
the sensitive and specific detection of VWA8 in MEFs was not found.
Overall, the accumulations of ClpX and five ClpX interactors were confirmed in
mitochondria, and ClpX with two interactors also showed similarly elevated abundance in
nuclear fractions.
3.5. Conserved ClpX-Dependent Effects in ClpP-Mutant Patient Skin Fibroblasts
Which of these mouse findings can be reproduced in human? Skin primary fibroblast
cultures were available to us from two patients with biallelic ClpP variants who had
markedly different disease severities (see Section 2). Immunoblots had shown ClpP to be
destabilized and absent in patient 58955 [37], making our ClpP mouse mutant a model of
this maximal PRLTS3 severity, while the mutation of ClpP in patient 0006 did not affect
its abundance and presumably reduces its function only partially, in correlation with
the difference in phenotypes above. Thus, the global proteome dysregulations might be
expected to be more dramatic in patient 58955 cells than in patient 0006 cells.
A completely novel documentation of the global proteome profile of primary skin
fibroblasts from these two PRLTS3 patients (average values, each in triplicate culture
samples) versus seven healthy controls (Table S6, volcano plot in Figure 4A) failed to
detect ClpP levels in every mutant cell triplicate upon mass spectrometry, while ClpP was
solidly detected in three out of seven controls. Reanalysis of the samples by immunoblots
confirmed ClpP to be almost absent only in the 58955 samples, and present at similar levels
in all control samples as well as in 0006 samples. Mass spectrometry found upregulated
abundances for the proteins ClpX (average 3.2-fold with p = 1.8 × 10−6; in the more severe
case, higher abundance by 1.7-fold), POLDIP2 (average 2.2-fold with p = 0.00002; severe
case had 1.5-fold more), LRPPRC (average 1.4-fold with p = 0.004; severe case had 1.5-fold
more), GFM1 (average 1.7-fold with p = 0.008; severe case had 1.7-fold more), GRSF1
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(average 5.3-fold with p = 0.0002; severe case had 1.1-fold more), and MRPS27 (average
1.1-fold with p = 0.02; severe case had 1.4-fold more). Among these factors, ClpP deficiency
affected ClpX as well as its interactors POLDIP2 and GRSF1, with a prominent effect size.
CHCHD2, VWA8, MRPS9, and MRPS22 proteins were below the detection threshold in
this mass spectrometry survey.
Systematic filtering of mitochondrial proteins that were upregulated at least 20% more
in the severe case than in the mild case was conducted to define the molecular correlates
of disease severity (Figure 4B). Strong enrichment upon STRING statistics was observed
for ClpX and other mitochondrial nucleoid-/RNA granule-associated factors (POLDIP2,
LRPPRC, FASTKD2, DHX30, MTPAP) [48,49], but not for mitoribosomal proteins. In
addition, the individual with the more severe phenotype showed stronger accumulation of
mitochondrial protein processing peptidase components, of 4-iron-4-sulfur cluster binding
and heme biosynthesis proteins, and of amino acid metabolism enzymes, with significant
enrichment upon STRING analysis (Figure 4B; the list of mitochondrial factors with stronger
accumulation in case 58955 and their enrichment statistics can be found in Supplementary
Table S7). Within amino acid metabolism, the valine/leucine/isoleucine, arginine/proline,
and glutamate/glutamine pathway components particularly stood out. Mitoribosomal
dysregulation was not prominent or consistent.
Some of these findings seem clearly mediated by ClpX accumulation and can occur
without ClpP alteration, in view of a previous report [50] where recombinant ClpX was
overexpressed 1.77-fold in mouse C2C12 myoblasts and proteome profiling then detected
accumulations of LRPPRC (1.66-fold), POLDIP2 (1.45-fold), GFM1 (1.62-fold), GRSF1 (1.38-
fold), FASTKD2 (1.58-fold), and MTPAP (1.41-fold). Thus, the accumulation of factors
with a known function at the mitochondrial nucleoid/RNA granule appears to be directly
dependent on ClpX excess.
3.6. Conserved Potentially ClpX-Independent Effects in ClpP-Mutant Patient Skin Fibroblasts
Testing the consistency between the proteome profiles of both PRLTS3 patient fibrob-
last cultures (in triplicates) versus ClpP-null MEFs, we also noted significant accumulations
of eleven mitochondrial matrix proteins (Figure 4C), which are not known as interactors of
ClpX or ClpB: OAT, ASS1, ACADVL, STOM, PRDX3, PC, MUT, ALDH2, PMPCB, UQCRC2,
and ACADSB, see Table 2. Importantly, all of them are known for their assembly into
homo-multimers or heterodimers [51–62]. OAT, PC, ALDH2, PMPCB, and ACADSB also
showed significant accumulation in ClpP-null brains (Table S3).
Beyond mass spectrometry, immunoblot analyses in fibroblast protein subcellular
fractions from the severely affected PRLTS3 female 58955 (where fold changes in abundance
can more easily be visualized in quantitative Western blots) and from the control female
red 128 were employed to assess data reproducibility in human (Figure 4D,E). Again,
accumulations were apparent for ClpX, POLDIP2, LRPPRC, GRSF1, GFM1 bands, and
CHCHD2 in the mitochondrial fraction. A nuclear accumulation of ClpX and its interactors
was not observed, even after using a titer of 1:100 of the anti-ClpX antibody that had
detected nuclear ClpX in MEF fractions. While it is therefore doubtful if excess ClpX in the
nucleus is a relevant event contributing to PRLTS3 pathogenesis, it may modify pathology
in the mouse model.
Cells 2021, 10, 3354 17 of 29
Figure 4. (A) Analysis of both PRLTS3 patients’ (in triplicates) versus 7 healthy controls’ skin
fibroblast proteome profiles in volcano plots, highlighting the accumulated proteins in mitochondria.
The significance threshold at 1.3 on the Y-axis corresponds to the p-value 0.05, and the X-axis
shows the traditional cut-off at 1.5-fold effects, although genetic evidence has demonstrated a
neurodegenerative process at old age to be triggered by a lower gain-of-function, such as 1.3-fold
dosage of alpha-synuclein. (B) Analysis of the differences between both patients in a STRING
interaction diagram, focused on mitochondrial proteins with significant accumulation in ClpP-
mutant patient skin fibroblast global proteome, which showed 1.2-fold stronger change in the severely
affected patient 58955 than in the milder patient 0006. (C) Comparison of all accumulations with
nominal significance in both PRLTS3 fibroblasts that showed consistency with nominal significant
accumulations in ClpP-null MEFs, using a Venn diagram. A total of 23 effects were consistent between
species, among which all mitochondrial proteins are listed below, employing their gene symbol.
(D) Analyses of protein abundance in fibroblasts from a human control (red128) and the patient with
stronger fold changes (58955), controlling the subcellular fractionation purity and loading by GAPDH
(cytosolic marker), HSP60 (mitochondrial), or LAMIN A/C (nuclear) abundance. (E) Quantitative
immunoblots for CLPX and its protein interactors confirmed their accumulation (e.g., 2.33-fold for
ClpX normalized to HSP60) to be restricted to mitochondria.
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Table 2. Significant accumulations of the above eleven mitochondrial matrix proteins were consistent between both PRLTS3
fibroblasts and ClpP-null MEFs, and partially consistent with ClpP-null brains (highlighted by gray background), although
they are not known as interactors of ClpX or ClpB. All of them show a multimerized quaternary structure, and they partly
associate with cofactors.
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3.7. Mass Spectrometry Quantification of Amino Acids in ClpP-Null MEFs
To understand the downstream consequences of the protein accumulations docu-
mented above, on the one hand, we assessed the impact of the potentially ClpX-independent
accumulation of OAT, ASS1, PC, MUT, and ACADSB on amino acid metabolism, and on
the other hand, we assessed the consequences of ClpX interactor excess on the nucleoids.
A metabolomics approach by mass spectrometry was taken to quantify the amino acid
concentrations in eight ClpP-null versus eight WT MEFs (Table S8, Figure S2), since pa-
tient fibroblast lines were not available in sufficient numbers to evaluate mild changes.
Although variability was high and future tissue analyses may be needed, the preliminary
data showed nominal significance (p < 0.05) for increased levels of leucine/isoleucine,
contrasting with decreased levels of methionine and histidine. These subtle and selective
effects are compatible with the mild phenotype of ClpP-mutant fibroblasts. Overall, litera-
ture and our proteome data suggest that specific multimeric complexes are affected (not the
bulk of monomeric enzymes) in the mitochondrial matrix of ClpP-mutant cells. However,
it has to be taken into account that a 30 kDa cut-off was used in the FASP methodology of
our mass spectrometry, so a technological bias might exist here, and further assessment of
this observation is necessary.
3.8. Nucleoid Misassembly in ClpP-Mutant Patient Fibroblasts
Next, we focused on pathology due to the ClpX interactor excess. Our prior work
had documented that deficiency of ClpP in mouse cells leads to mtDNA instability and
nucleoid enlargement, but whether these features could be recapitulated in Perrault syn-
drome patients is unknown [17]. Nucleoid staining in human fibroblasts from a control
(Red128) and a PRLTS3 patient (CLPP-mutant patient 58955) showed mtDNA stress and
Cells 2021, 10, 3354 19 of 29
packaging alterations in the PRLTS3 patient (Figure 5A), with significant nucleoid enlarge-
ment (Figure 5B). Similar to ClpP-null MEFs, PRLTS3 patient cells also showed a significant
increase in the mtDNA copy number (Figure 5C), assessed by qPCR with ND1 and DLoop1
mitochondrial DNA primers.
Figure 5. Nucleoid misassembly in PRLTS3 fibroblasts. (A) Immunocytochemistry with HSP60 as
a mitochondrial marker (purple) and DAPI as a nuclear marker (blue) showed PRLTS3 fibroblasts
with a larger TFAM-positive area (red) that contain multiple mitochondrial DNA signals upon
deconvolution (green). (B) Quantification of nucleoid size showed significant enlargement. (C) Copy
number quantification by qPCR for two sites within mtDNA also revealed significant increases.
** p < 0.01; **** p < 0.0001.
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4. Discussion
Our study attempted to define mitochondrial ClpP-mediated degradation substrates
in mouse and human. This goal was first approached by consistency criteria, comparing
proliferating peripheral cells with glycolytic profiles from two organisms to murine ner-
vous tissue containing postmitotic neurons that have a respiratory profile. To distinguish
primary events from secondary consequences, high-quality protein interaction data from
the BioGrid database were used to identify the ClpX protein interactors that accumulate
upon ClpP inactivity (Figure 1). In a second approach, the fold-changes of accumulation
of mitochondrial proteins were correlated with disease severity in two PRLTS3 patients
(Figure 4B). Each strategy came to the conclusion that the primary effects of ClpP inactivity
involve ClpX interactor proteins at the nucleoid and mitochondrial RNA granule (Figure 6).
The fold-changes of accumulation were much stronger for these proteins than what was
previously observed for ClpP modulation of mitoribosome components, and, naturally, the
observed nucleoid/RNA granule pathology might affect mitoribosomal translation as a
downstream consequence. Numerous previous efforts to define ClpP-mediated degrada-
tion substrates had been unable to identify consistent results across species and techniques
employed, so we wonder to what degree the interactions between ClpX and its target
protein/RNA/DNA complexes may be lost during the different co-immunoprecipitation
and extraction procedures used.
Figure 6. Schematic overview of potential mechanisms in the presence (A) and absence (B) of ClpP. ClpP inactivating
variants act via ClpX accumulation on mitochondrial nucleoid/RNA granule components, triggering excess POLDIP2,
LRPPRC, GFM1, GRSF1, and mtDNA abundance, as well as an enlarged nucleoid area, as a clear result of this study. Less
consistent across cell types and potentially without ClpX interactions, multimerizing enzymes in the matrix also show
increased abundance. In parallel, elevated levels of varying molecular chaperones suggest a mitochondrial unfolded protein
response and aggregation tendencies. OAT multimer and nucleoid shapes were adapted from Refs. [63,64].
As a first key finding, ClpP pathogenic variants trigger the protein accumulation of
POLDIP2, LRPPRC, and GFM1 with high consistency between mammalian species and cell
types. While POLDIP2 functions at the nucleoid and LRPPRC at the mitochondrial RNA
granule modulating polyadenylation [41,42,65,66], GFM1 directly acts at mitoribosomes,
and its excess was shown to impair translation [44,67,68]. Mitoribosomal dysfunction is con-
sidered a crucial site of pathology in Perrault syndrome, and these events occur upstream.
In addition, the mouse proteome profiles identified the ClpP-dependent accumulation of
GRSF1 as prominent (in ClpP-null MEFs, 4.6-fold and highly significant; in ClpP-null brain
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pellets, 2.1-fold with actual significance; in ClpP-null brain supernatants, 1.8-fold with a
statistical trend p = 0.06; in human fibroblasts, it was detected only in two out of seven
controls and was therefore ignored by the filtering algorithm, but imputation revealed a >5-
fold highly significant accumulation). GRSF1 acts with RNase P to process mitochondrial
polycistronic precursor RNA into tRNAs/mRNAs/rRNAs and lncRNAs [43,69]. GRSF1
associates with Twinkle in the mitochondrial RNA granule [5] and controls the translation
of mRNAs with G-repeats in front of the start codon [70,71]. Thus, GRSF1 connects ClpXP
with Twinkle and tRNA maturation in mitochondrial RNA granules. Our crucial novel
insight of ClpP-dependent GFM1 and GRSF1 abundance therefore suggests a common
pathway for Perrault syndrome pathogenesis, since the genetic causes of autosomal reces-
sive Perrault syndrome include variants in the mitochondrial tRNA amino acid synthetases
HARS2 and LARS2, the mitochondrial tRNA processing enzyme PRORP, the mitochondrial
DNA/RNA helicase/primase TWNK, and the peptidase ClpP. It is noteworthy that none of
the Perrault syndrome disease proteins were dysregulated, except HSD17B4 that showed
a significant upregulation only in patient fibroblasts, meaning the role of ClpP cannot be
explained by abnormal degradation of a Perrault syndrome disease protein, by this dataset.
A second key finding is the relocation of excess amounts of ClpX and its interac-
tors such as GFM1 and GRSF1 outside mitochondria. This might represent an additional
mechanism of how retrograde signals about mitochondrial needs and pathology reach
the nucleus, in the context of UPRmt but independent of transcriptional regulation, influ-
encing the abundance of nuclear/nucleolar proteins and affecting the whole cell. This
ClpX redistribution was observed only in mouse and was not demonstrable in patient
fibroblasts. As a similar difference between mouse and human, it is interesting to note that
the ClpP-null MEFs showed a massive induction of the innate immune defense against
toxic DNA/RNA, while the patient fibroblasts did not show such immunostimulation.
GRSF1 has a physiological presence in the nucleus, as with other members of the hnRNP
F/H family [72], but its function there is not clear. GRSF1 abundance is physiologically
controlled by DAZL [73], the master translational regulator of spermatogenesis [74,75]. It
is known that a G4-repeat DNA structure resolvase named RHAU is essential for spermato-
gonia differentiation via c-Kit [76]. Furthermore, GRSF1 targets the G-repeat-containing
mRNA of GPx4 [77], a crucial factor for protamine-mediated chromatin condensation
during spermatogenesis [78]. Thus, it is conceivable that dysregulated GRSF1 abundance
interferes with germ cell differentiation, meiosis, and sperm capacitation in PRLTS3. Pri-
mary ovarian insufficiency is also observed upon mutation of the mitochondrial tRNA
synthetases HARS2, LARS2, and PRORP, meaning that, apparently, other mitochondrial
tRNA processing alterations may also influence meiotic events in the nucleus.
The weakest effect of ClpP deletion on a ClpX interactor in the above experiments
was observed for the PD-associated UPRmt sensor CHCHD2 [25,45], in agreement with
previous observations that ClpP-null mice do not show widespread strong UPRmt [79] or
the typical distribution of PD pathology [2,80].
As a third key finding, ClpP deletion across species and cell types consistently triggers
the accumulation of homo/hetero-multimerizing enzymes in the mitochondrial matrix such as
OAT, ASS1, ACADVL, STOM, PRDX3, PC, MUT, ALDH2, PMPCB, UQCRC2, and ACADSB.
ClpP-dependent OAT accumulation stands out and was already proposed, together with
POLDIP2, as a putative ClpP substrate in a previous mouse fibroblast proteome study [12], al-
though it was never found to interact with ClpX. The putative ClpP substrate PMPCB forms het-
erodimers with PMPCA and has a key role in mitochondrial precursor protein cleavage/folding
as well as presumably UPRmt, in a very similar manner to its homologous cleavage factor
UQCRC2 that forms heterodimers with UQCRC1 and is crucial for respiratory complex III
assembly. The observation of normal levels for valine, arginine/proline, glutamate/glutamine,
and, in particular, ornithine in our ClpP-null MEFs suggests normal enzymatic activity remains
for OAT even though it is accumulated and although the OAT hexamer might be misassem-
bled. Additionally, a previous study of Podospora anserina ClpP deletion mutants also observed
increased leucine/isoleucine, as opposed to decreased histidine levels [81]. The previously
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reported metabolome data in PRLTS3 patient 58955, where urinary excretion contained excess
amounts of fumarate and oxo-glutarate [37], suggest that carbon flux in the TCA cycle occurs
at high levels, possibly at the expense of specific amino acids as well as glucose. Abnormal
assembly of UQCRC2 in mitochondrial complex III could easily explain why its respiratory
activity was mildly low in a muscle biopsy of PRLTS3 patient 58955 [37]. High-throughput
phenotype screening of the ClpP-null mouse organism previously revealed decreases in circu-
lating glucose and insulin levels versus increases in circulating cholesterol and bilirubin levels
(https://www.mousephenotype.org/data/genes/MGI:1858213#phenotypesTab, accessed on
27 October 2021). Additionally, studies of the metabolome in the ClpP-deficient microorganism
Bacillus subtilis showed elevated levels for most glycolytic metabolites and TCA intermedi-
ates [13,82–84].
Although the accumulation of MUT was mild in our mass spectrometry and im-
munoblot data, it correlates best with the metabolome findings of elevated methylmalonyl-
CoA and isoleucine levels in ClpP-mutant fibroblasts. MUT acts on methylmalonyl-CoA
that is derived from degraded branched-chain amino acids such as isoleucine, isomerizing
it to succinyl-CoA as a substrate for the TCA cycle. Given that MUT has to assemble
into homodimers with GTPase-assisted binding to vitamin B12 [85], its optimal activity
may not be achieved upon chaperone/disaggregase excess, leading to accumulations of
dysfunctional MUT, its substrate methylmalonyl-CoA, and its precursor isoleucine. The
reduced levels of methionine as a start codon for protein synthesis might mirror inefficient
ribosomal translation. Alternatively, the reduction in methionine together with histidine
might point to altered glucogenic metabolism. However, we want to caution against over-
interpretation of our metabolomics findings, since 3 alterations with nominal significance
among the 54 metabolites investigated might simply be explained away as multiple testing
artifacts, or a false positive result.
The accumulation of these proteins that have to multimerize after mitochondrial
import could represent a secondary consequence of the UPRmt stress in fibroblasts that
predominantly use glycolysis, where altered abundance of varying molecular chaperones
and altered pH can conspire to impair the maturation of functional multimer complexes.
However, in the light of our search for ClpP substrates that accumulate in PRLTS3 cells, we
might also assess these factors as potential primary targets of ClpP dysfunction, possibly
independent of ClpX. Thus, these proteins might shed light on ClpP’s basic function. It
is important to know that ClpP, by itself, has the capacity to digest small peptides, pref-
erentially with hydrophobic/aromatic residues, in a chymotrypsin-like manner [13,83]
and it is therefore classified as a peptidase, until its association with ClpX enables it to
degrade complete proteins as a protease. Thus, it is conceivable that the specificity pockets
of ClpP heptamers target hydrophobic peptides in between target multimeric proteins
to cleave their interaction domains and regulate their activity, as a rapid stress response
inside mitochondria long before the cell nucleus can induce alternative allelic splice iso-
forms of mitochondrial factors that may compensate stress. Such a phenomenon has been
reported for the nucleoid-interacting protein Twinkle, whose mutations can also trigger
Perrault syndrome, and which was unfortunately not detected in our mass spectrome-
try dataset with current methods. The hexameric structure and nucleoid associations of
Twinkle depend on its C-terminal sequences, and an alternatively spliced isoform named
Twinky was observed to exist as a monomer that is diffusely distributed throughout the
mitochondrial matrix [84]. Clearly, the role of ClpP for Perrault syndrome might become
more understandable if its dysfunction controls the abundance/multimerization/target
interaction/activity of the PRLTS disease protein Twinkle at the nucleoid. Thus, we pos-
tulate that a hypothetical role of ClpP peptidase for target multimerization is compatible
with current knowledge and relevant enough to be investigated deeply in future targeted
experiments. Altogether, our proteome profiles and BioGrid data are compatible with a
scenario where ClpP, by itself, acts, e.g., on the OAT homohexamer that is stably associated
with pyridoxal phosphate in the mitochondrial matrix, and ClpB assists the disaggregation
of mitoribosomes, while ClpX mediates the targeting of mitochondrial nucleoids together
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with adjacent RNA granules. ClpX might select substrates for ClpP-mediated cleavage
during the assembly and disassembly of mitochondrial DNA/rRNA/mRNA/tRNA with
proteins in these complexes.
As a fourth key finding, human cells from ClpP-mutant PRLTS3 patients show an
enlarged nucleoid area and thus confirm the significant role of ClpP in the maintenance of
mtDNA/protein complex assembly and distribution, which was previously observed in
mouse cells with ClpP deficiency. Here, it is interesting to note that ClpX was previously
reported to modulate the genome distribution in mitochondria, and to enhance the DNA-
binding activity of TFAM as a requirement for maintaining a normal mitochondrial nucleoid
structure [86]. The phenotype observed in PRLTS3 patient cells indicates a potential role
for mtDNA stress in the pathogenesis of Perrault syndrome, a scenario that has not been
explored before. These findings indicate a conserved role for ClpP in mtDNA homeostasis
that might have implications for downstream mitochondrial transcription and translation,
and for downstream activation of innate immunity via cGAS.
Considering all data and the literature, we speculate that the selective accumulation
of mtDNA copies in nucleoids and of multimerizing enzymes in the matrix in ClpP-mutant
cells may suggest that ClpP acts to restrict unwanted further self-assembly, once the appro-
priate degree of multimerization or the appropriate number of supercoiled DNA rings per
nucleoid is reached. According to this notion, ClpP function would limit multimerization
and would counteract aggregation and fibril formation in the mitochondrial matrix, rather
than having a responsibility for the degradation of bulk proteins, as with the mitochondrial
matrix protease LonP1.
Overall, the present data concur with previous evidence that the PRLTS3 pathology
is dominated by improper handling of nucleic acids by proteins, leading to nucleoid
pathology in mouse and human, as shown here, as well as distorted responses of cytosolic
immune sensors to toxic nucleic acids, at least in mouse cells, as reported before [17,29].
In comparison, the decrease in metabolites is minor and does not seem to explain the
substantial growth deficit of ClpP-deficient organisms.
5. Conclusions
Overall, our analysis of accumulated mitochondrial factors in ClpP mutants, which
are consistent across species and cell types, defined several putative substrates of ClpP-
mediated degradation. Among them, POLDIP2, LRPPRC, and GFM1 interact with ClpX
disaggregase and are therefore particularly credible as primary targets of ClpXP function;
their roles for mitochondrial nucleoids and RNA granules explain how nucleoids become
misassembled in PRLTS3, as the most important functional impact revealed by our study.
The excessive amounts of ClpX and its interactors such as GFM1 and GRSF1 relocalize
to the nucleus in ClpP-null mouse fibroblasts, possibly redistributed there by the large
amount of protein/DNA/RNA complexes as docking stations. In contrast, the fibroblast-
selective accumulation of multimerizing, often vitamin-associated factors such as OAT,
MUT, PMPCB, UQCRC2, PC, ACADVL, PRDX3, ASS1, ALDH2, ACADSB, and STOM
in ClpP-null mice may be an indirect downstream feature due to the dysregulation of
molecular chaperones under conditions of UPRmt, or it might potentially be a direct
effect independent of ClpX, but it clearly has only a minor impact on metabolism under
unstressed conditions.
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ACADSB Acyl-CoA Dehydrogenase, Short/Branched Chain Specific
ACADVL Acyl-CoA Dehydrogenase, Very-Long Chain
ALDH2 Aldehyde Dehydrogenase, Mitochondrial Isoform
ANOVA analysis of variance
ASS1 Argininosuccinate synthase 1
BCA bicinchoninic acid assay
cGAS Cyclic GMP-AMP Synthase
CHCHD2 Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 2
c-kit tyrosine-protein kinase KIT
ClpB Caseinolytic Mitochondrial Matrix Peptidase Chaperone Subunit B
ClpP Caseinolytic Mitochondrial Matrix Peptidase Proteolytic Subunit
ClpX Caseinolytic Mitochondrial Matrix Peptidase Chaperone Subunit X
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DAZL Deleted In Azoospermia Like
DMEM Dulbecco’s modified Eagle medium
Dnaja3 DnaJ Heat Shock Protein Family (Hsp40) Member A3
EDTA Ethylenediaminetetraacetic acid
Eral1 Era Like 12S Mitochondrial RRNA Chaperone 1
ESI electrospray ionization
FBS fetal bovine serum
GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase
GFM1 G Elongation Factor Mitochondrial 1
GPx4 Glutathione Peroxidase 4
GRSF1 G-Rich RNA Sequence Binding Factor 1
HARS2 Histidyl-TRNA Synthetase 2, Mitochondrial
hnRNP Heterogeneous Nuclear Ribonucleoprotein
Hsd17b4 Hydroxysteroid 17-Beta Dehydrogenase 4
HSP60 Heat Shock Protein Family D (Hsp60) Member 1
LARS2 Leucyl-TRNA Synthetase 2, Mitochondrial
lncRNA long non-coding RNAs
LRPPRC Leucine Rich Pentatricopeptide Repeat Containing
MEFs mouse embryonic fibroblasts
MRM multiple reaction mode
mRNA messenger RNA
MRPS22 Mitochondrial Ribosomal Protein S22
MRPS27 Mitochondrial Ribosomal Protein S27
MRPS9 Mitochondrial Ribosomal Protein S9
mtDNA mitochondrial DNA
MUTn Methylmalonyl-CoA Mutasetotal sample number
OAT Ornithine Aminotransferase
OXR1 Oxidation Resistance 1
PC Pyruvate Carboxylase
PCR polymerase chain reaction
PD Parkinson’s disease
PMPCA Peptidase, Mitochondrial Processing Subunit Alpha
PMPCB Peptidase, Mitochondrial Processing Subunit Beta
POLDIP2 DNA Polymerase Delta Interacting Protein 2
PRORP Protein Only RNase P Catalytic Subunit
PRLTS Perrault syndrome
RHAU RNA Helicase associated with AU-rich element
RIPA Radioimmunoprecipitation assay buffer
RNA ribonucleic acid
rRNA ribosomal RNA
SDS sodium dodecyl sulfate
SEM standard error of the mean
STING Stimulator Of Interferon Genes
STOM stomatin
STRING Search Tool for Recurring Instances of Neighboring Genes
TCA cycle tricarboxylic acid cycle
Tbp TATA-Box Binding Protein
tRNA transfer RNA
Twnk Twinkle
UPRmt unfolded protein response, mitochondrial
UQCRC2 Ubiquinol-Cytochrome C Reductase Core Protein 2
UQCUC1 Ubiquinol-Cytochrome C Reductase Core Protein 1
VWA8 Von Willebrand Factor A Domain Containing 8
WT wild type
ZFE central animal facility
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